Stylized image of an eye transforming into a healthy landscape, symbolizing diabetic retinopathy prevention.

Diabetic Retinopathy Screening: A Comprehensive Guide to Danish Guidelines

Lena Voss monogram
Lena Voss in Health & Wellness October 2026 • 4 min read.

"Navigate the latest evidence-based recommendations for diabetic retinopathy screening, tailored to empower patients and optimize eye health management."


Diabetic retinopathy (DR) is a leading cause of vision loss among working-age adults, but early detection and timely treatment can significantly reduce this risk. Regular screening plays a crucial role in identifying DR before it causes irreversible damage, making it essential for individuals with diabetes to understand the latest screening guidelines.

In Denmark, the Danish Ophthalmological Society has developed contemporary, evidence-based guidelines for DR screening, designed to ensure high-quality care and optimize resource allocation. These guidelines, updated as of 2018, offer a flexible, individualized approach to screening, taking into account each patient's unique risk factors and disease progression.

This article breaks down the key aspects of the Danish guidelines, providing clear and actionable information to help patients and healthcare providers navigate the complexities of DR screening. We'll explore the classification of DR, effective examination techniques, recommended screening intervals, and the potential role of automated screening in the future.

AI Search Multiple angles on this topic

Screening Methods and Limitations

The American Academy of Ophthalmology identifies dilated fundus examination as the gold standard for diabetic retinopathy screening, while validated digital imaging may also be effective. Diabetic retinopathy can remain asymptomatic for years, even at an advanced stage, making screening important for identifying and monitoring disease. Researchers have evaluated strategies using smaller fields of view, including fewer than seven retinal fields, but this approach still requires further validation.

The Evolution of Screening

Diabetic retinopathy screening has evolved through major changes in healthcare infrastructure, telemedicine approaches, and imaging devices. A 2025 review describes a shift from specialist-led screening toward generalist models and the adoption of telemedicine to expand access and improve efficiency. Longitudinal research also followed adults in Beaver Dam, Wisconsin, to measure the prevalence and incidence of common eye diseases in an aging population.

Understanding Diabetic Retinopathy Classification: What the Levels Mean

Stylized image of an eye transforming into a healthy landscape, symbolizing diabetic retinopathy prevention.

The Danish guidelines recommend using the International Clinical Diabetic Retinopathy Disease Severity Scale to classify DR. This scale helps doctors determine the severity of your condition and the appropriate course of action. It ranges from Level 0 (no DR) to Level 4 (proliferative DR), with each level indicating a different stage of the disease.

Here's a breakdown of what each level signifies:

  • Level 0: No DR. This indicates that there are no signs of diabetic retinopathy.
  • Level 1: Mild Non-Proliferative DR (NPDR). Only microaneurysms and/or dot hemorrhages are present.
  • Level 2: Moderate NPDR. More microaneurysms and/or dot hemorrhages are present, but less than Level 3.
  • Level 3: Severe NPDR. Characterized by more than 20 intraretinal hemorrhages in each of 4 quadrants, or definite venous beading in at least 2 quadrants, or prominent IRMA in at least 1 quadrant.
  • Level 4: Proliferative DR (PDR). New blood vessel growth (neovascularization) is present, or there is evidence of vitreous or pre-retinal hemorrhage.
AI Search Multiple angles on this topic

Refining National Screening

A review published by Ugeskriftet describes changes in Denmark's national diabetic eye-screening programme. The programme's focus has been adapted to avoid excessive screening while retaining patients within the screening system. This reflects an effort to balance appropriate surveillance with continued patient participation.

Screening Needs and Disease Burden

Traditional in-office screening may not meet future demand because diabetes prevalence is increasing and the supply of medically trained ophthalmic providers is projected to fall short. Data from DiaBase's 2014–2015 annual report found 78% of recorded patients had no diabetic retinopathy, 18% had nonproliferative diabetic retinopathy, and 4% had proliferative diabetic retinopathy. Screening frequency can vary substantially by disease status, with some people requiring comprehensive dilated eye examinations every 2 to 4 months.

In addition to these levels, the guidelines also classify diabetic macular edema (DMO), which is swelling in the macula (the central part of the retina). Clinically significant macular edema (CSMO) requires prompt referral for treatment to prevent vision loss. DMO is differentiated into with and without CSMO.

Empowering Patients Through Knowledge

By understanding the Danish guidelines for diabetic retinopathy screening, individuals with diabetes can take proactive steps to protect their vision. Regular screening, combined with good diabetes management, offers the best chance of preventing vision loss from this common complication.

AI Search Multiple angles on this topic

AI and Telehealth

Experts describe gaps in care and the growing global diabetes epidemic as reasons to improve existing diabetic retinopathy screening and treatment. Research and commentary in 2026 highlight AI retinal imaging, telehealth models, and early detection strategies in primary care as emerging directions. One ophthalmology source reports that early screening could prevent 99% of severe proliferative diabetic retinopathy cases.

AI in Real-World Care

Real-world studies are evaluating whether validated artificial-intelligence diabetic retinopathy screening algorithms can be integrated into outpatient public-health settings. AI-based retinal image analysis is presented as a promising response to the growing global burden of diabetes and the resulting pressure on ophthalmic services. A study by Shah and colleagues validated the IDx autonomous diabetic retinopathy screening programme in a real-world setting.

Screening intervals in context

  • one to four yearsFor people with no retinopathy at baseline, evaluations found appropriate screening intervals ranging from one to four years.[1]
  • annual versus 2 yearsThree studies reported similar actual or predicted incidence and progression with annual versus 2-yearly screening.[2]
  • 24–48; 12–24 monthsFor no or mild NPDR, Danish guidance allows intervals of 24–48 months; for moderate NPDR, it allows 12–24 months when glycaemic control and blood pressure meet the stated thresholds.[3]

How interval evidence and screening methods compare

A trial comparing individualised screening with control reported similar first follow-up attendance, and sight-threatening retinopathy detection met its non-inferiority criterion in the individualised arm. This offers a direct comparison of an adapted schedule with control, rather than a general estimate for all screening programmes.[4]

Automated screening was described as encouraging but not ready for implementation, while a later primary-care validation raised concerns about image quality and failure to consistently identify ungradable images. Together, these sources distinguish promise from demonstrated readiness for safe routine use.[3] [5]

What screening evidence still needs to clarify

  • How well do interval comparisons generalize across patient groups and screening settings, given that the interval review found its data too heterogeneous for meta-analysis?[6]
  • Can automated systems reliably identify ungradable images and maintain diagnostic safety when used in real-world screening, given the reported implementation concern and Danish guidance that automation was not yet ready?[3] [5]

Sources

  1. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. (pubmed.ncbi.nlm.nih.gov)
  2. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review (pmc.ncbi.nlm.nih.gov)
  3. Evidence-based Danish guidelines for screening of diabetic retinopathy. (pubmed.ncbi.nlm.nih.gov)
  4. Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT (pmc.ncbi.nlm.nih.gov)
  5. The diagnostic accuracy of AI-assisted diabetic retinopathy screening in primary care: a prospective validation study (pmc.ncbi.nlm.nih.gov)
  6. A systematic review of diabetic retinopathy screening intervals. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are the Danish guidelines for diabetic retinopathy screening, and why are they important?

The Danish guidelines for diabetic retinopathy (DR) screening are evidence-based recommendations developed by the Danish Ophthalmological Society. These guidelines aim to ensure high-quality care and optimize resource allocation in the screening process. They offer a flexible, individualized approach, considering each patient's unique risk factors and disease progression. Following these guidelines is important as diabetic retinopathy is a leading cause of vision loss among working-age adults, and regular screening helps in early detection and timely treatment, significantly reducing the risk of irreversible damage. Understanding and adhering to these guidelines empowers individuals with diabetes to take proactive steps in protecting their vision.

2

What is the International Clinical Diabetic Retinopathy Disease Severity Scale, and why is it used in the Danish guidelines?

The International Clinical Diabetic Retinopathy Disease Severity Scale is a classification system used within the Danish guidelines to determine the severity of diabetic retinopathy. It ranges from Level 0 (no DR) to Level 4 (proliferative DR), with each level indicating a different stage of the disease. Additionally, diabetic macular edema (DMO) is classified based on the presence of clinically significant macular edema (CSMO). This classification is significant because it helps doctors determine the appropriate course of action and referral for treatment, particularly in cases of CSMO, to prevent vision loss.

3

Can you explain the different levels of diabetic retinopathy according to the International Clinical Diabetic Retinopathy Disease Severity Scale?

The different levels of diabetic retinopathy, as defined by the International Clinical Diabetic Retinopathy Disease Severity Scale, are: * Level 0: No DR, indicating no signs of diabetic retinopathy. * Level 1: Mild Non-Proliferative DR (NPDR), characterized by the presence of microaneurysms and/or dot hemorrhages. * Level 2: Moderate NPDR, with more microaneurysms and/or dot hemorrhages than Level 1, but less than Level 3. * Level 3: Severe NPDR, defined by more than 20 intraretinal hemorrhages in each of 4 quadrants, or definite venous beading in at least 2 quadrants, or prominent IRMA in at least 1 quadrant. * Level 4: Proliferative DR (PDR), where new blood vessel growth (neovascularization) is present, or there is evidence of vitreous or pre-retinal hemorrhage. These levels are important because they help in staging the progression of the disease, guiding treatment decisions and determining the appropriate screening intervals.

4

What is diabetic macular edema (DMO), and why is clinically significant macular edema (CSMO) a concern?

Diabetic macular edema (DMO) refers to swelling in the macula, the central part of the retina responsible for detailed central vision. Clinically significant macular edema (CSMO) is a specific classification of DMO that requires prompt referral for treatment. The presence of CSMO is particularly significant because it indicates a higher risk of vision loss. Early detection and treatment of CSMO are crucial in preventing further damage to the macula and preserving vision.

5

What examination techniques are used for diabetic retinopathy screening, according to the Danish guidelines?

While the article focuses on classification and understanding of diabetic retinopathy according to the Danish guidelines, it does not explicitly detail the specific examination techniques used for screening. However, it implies that regular screening is essential. These techniques typically include fundus photography, optical coherence tomography (OCT), and clinical examination by an ophthalmologist. The role of automated screening is also mentioned as a potential area for future development to improve the efficiency and accessibility of DR screening.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.